Getinge AB
STO:GETI B

Watchlist Manager
Getinge AB Logo
Getinge AB
STO:GETI B
Watchlist
Price: 180.15 SEK 0.92% Market Closed
Market Cap: 49.1B SEK
Have any thoughts about
Getinge AB?
Write Note

Getinge AB
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Getinge AB
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Getinge AB
STO:GETI B
Total Equity
kr30.2B
CAGR 3-Years
13%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Elekta AB (publ)
STO:EKTA B
Total Equity
kr10.8B
CAGR 3-Years
10%
CAGR 5-Years
7%
CAGR 10-Years
N/A
S
Surgical Science Sweden AB
STO:SUS
Total Equity
kr4.4B
CAGR 3-Years
9%
CAGR 5-Years
63%
CAGR 10-Years
N/A
CellaVision AB
STO:CEVI
Total Equity
kr767.9m
CAGR 3-Years
15%
CAGR 5-Years
19%
CAGR 10-Years
19%
Arjo AB (publ)
STO:ARJO B
Total Equity
kr7.6B
CAGR 3-Years
10%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Sedana Medical AB (publ)
STO:SEDANA
Total Equity
kr950m
CAGR 3-Years
23%
CAGR 5-Years
35%
CAGR 10-Years
N/A
No Stocks Found

Getinge AB
Glance View

Market Cap
49.1B SEK
Industry
Health Care

Getinge AB, rooted in the lush landscapes of Sweden, has steadily evolved into a global leader in the medical technology sector. The company began its journey by manufacturing traditional sterilizers over a century ago. Over time, Getinge has carefully navigated and adapted to the ever-changing dynamics of the healthcare industry, positioning itself squarely at the intersection of innovation and practicality. Today, Getinge specializes in a broad spectrum of medical equipment and systems, focusing on critical care, surgery, and infection prevention. This focus is intricately designed to cater to hospitals and healthcare facilities worldwide, ensuring that patients receive the highest standard of care during complex procedures and critical conditions. Revenue streams for Getinge are as diversified as its product portfolio, comprising equipment sales, service contracts, and consumables. The company’s product offerings range from sophisticated ventilators and state-of-the-art heart-lung machines, to efficient sterilization and surgical workflow products. Beyond simply selling devices, Getinge builds sustainable revenue through long-term service agreements and the sale of replacement parts and consumables, which are essential for the ongoing, optimal operation of its technologically advanced machinery. This strategic emphasis on combining cutting-edge product development with a robust support infrastructure underscores Getinge’s business model, ensuring loyalty and ongoing relationships with healthcare institutions globally.

GETI B Intrinsic Value
282.45 SEK
Undervaluation 36%
Intrinsic Value
Price

See Also

What is Getinge AB's Total Equity?
Total Equity
30.2B SEK

Based on the financial report for Dec 31, 2023, Getinge AB's Total Equity amounts to 30.2B SEK.

What is Getinge AB's Total Equity growth rate?
Total Equity CAGR 5Y
9%

Over the last year, the Total Equity growth was 0%. The average annual Total Equity growth rates for Getinge AB have been 13% over the past three years , 9% over the past five years .

Back to Top